Related Experiment Video
Updated: Oct 13, 2025
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon
Francesco Passiglia1, Valentina Bertaglia1, Maria Lucia Reale1
1Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy.
Abstract:
We are witnessing a silent revolution in the treatment of early stage non-small cell lung cancer (NSCLC), with a series of practice-changing clinical trials enriching the therapeutic perspectives of lung cancer patients with potentially curable disease. The ADAURA study marked the advent of precision medicine and biomarker testing to the early stages setting. The IMPower-010 trial interrupted the negative trend of adjuvant lung cancer immunotherapy, paving the way to the application of immune-checkpoint inhibition in the resected disease. The ITACA trial definitively established no role for tailored adjuvant chemotherapy in NSCLC, while the Lung Art data questioned the efficacy of post-operative radiotherapy for pN2 resected disease. Growing evidence is supporting MRD as effective adjuvant prognostic biomarker to stratify disease's recurrence risk after radical interventions and select best candidates to the adjuvant strategies. This work summarizes the recent major breakthroughs in lung cancer adjuvant treatment, and provides a snapshot of the current real-world scenario, discussing the upcoming challenges and opportunities featuring the clinical management of early stage NSCLC patients.
Insights
Recent trials revolutionize early-stage non-small cell lung cancer (NSCLC) treatment. Adjuvant immunotherapy and precision medicine are now key, while tailored chemotherapy and radiotherapy roles are redefined, improving patient outcomes.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Oncology
Background:
- Early-stage non-small cell lung cancer (NSCLC) treatment is evolving rapidly.
- Practice-changing trials are redefining adjuvant strategies for resectable NSCLC.
- Biomarker-driven approaches are increasingly important in early-stage disease.
Purpose of the Study:
- To summarize recent breakthroughs in adjuvant treatment for early-stage NSCLC.
- To provide an overview of the current clinical landscape.
- To discuss future challenges and opportunities in NSCLC management.
Main Methods:
- Review of pivotal clinical trials (ADAURA, IMPower-010, ITACA, Lung Art).
- Analysis of emerging biomarkers, including minimal residual disease (MRD).
- Synthesis of current evidence and real-world data.
Main Results:
- Adjuvant immunotherapy (IMPower-010) shows efficacy in resected NSCLC.
- Precision medicine (ADAURA) is established in early stages.
- Tailored adjuvant chemotherapy (ITACA) and post-operative radiotherapy (Lung Art) have limited roles.
- MRD is emerging as a prognostic biomarker for recurrence risk stratification.
Conclusions:
- The adjuvant treatment landscape for early-stage NSCLC has been significantly reshaped by recent trials.
- Precision medicine, immunotherapy, and MRD-based risk stratification are key components of modern adjuvant therapy.
- Continued research is needed to optimize treatment selection and improve outcomes for NSCLC patients.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers